Like other glucocorticoids, prednicarbate binds to specific receptors after entering the cell, forming a complex. This enters the nucleus and subsequently causes altered gene expression and greater expression of proteins that inhibit the enzyme phospholipase A2. These proteins, known as lipocortins, can control inflammation in the human body by inhibiting the release of arachidonic acid (the precursor of pro-inflammatory prostaglandins and leukotrienes).
After topical application, prednicarbate is converted while still in the skin to the much more potent prednisolone-17-ethylcarbonate. This is degraded to prednisolone, metabolized in the liver and excreted renally.
Prednicarbate should not be administered in the presence of hypersensitivity to the active ingredient.
To avoid worsening of the clinical picture, prednicarbate should not be used in:
- Vaccine reactions
- Bacterial skin diseases
- Perioral dermatitis
- Skin ulcers
During pregnancy, large-area application of prednicarbate should be avoided, and during lactation, the active ingredient should not be applied to the breast area.